Image from the web
Billion Euro on February 6th, the listed company Zhongyuan Xiehe announced today that it signed the "Equity Transfer Agreement" with Straits Investment yesterday and decided to hold Beijing Panshengzi Gene Technology Co., Ltd. (hereinafter referred to as "the ubiquitous gene"). 6.483% equity, corresponding to the registered capital of 4,600,600 yuan, was transferred to Shenzhen Strait Life Science Investment Partnership (Limited Partnership) (hereinafter referred to as "Strait Investment") at a price of 125 million yuan.
The announcement stated that the Straits Investment was established on July 3, 2017 with a registered capital of 10 million yuan, total assets of 212 million yuan, net assets of 210 million yuan, operating income of 0 million yuan in 2017, and net profit of -456.69 million yuan. There is no relationship between property rights, business, assets, credits, debts, personnel, etc. between Straits Investment and Zhongyuan Concord.
The Panshengzi was established on May 7, 2015, and the legal representative is Wang Sizhen. Mainly engaged in the health management of all aspects of cancer cycle diagnosis (risk assessment, early screening, molecular diagnosis and postoperative monitoring, etc.), providing molecular diagnosis and treatment programs, professional cancer genetic risk assessment.
The announcement shows that the generic gene has been replenished twice in October and December 2017, and the investment shareholders, Jinchuang Junhe, Zhongjin, Yuanxing, Shenshang Xingye, Baichuan Huida and Jiadao, respectively subscribed for new registrations. The capital was 4,145,500 yuan, 8,833,100 yuan, 1,472,200 yuan, 883,300 yuan, 294,400 yuan, and 589,900 yuan.
In September 2016, Yiou had reported that Zhongyuan Xiehe had increased its share of the generic gene by 100 million yuan, holding 10% of its shares, and at the same time, it was transferred to a 5% stake held by Jinchuang Junlian for 23 million yuan. In other words, after the capital increase and transfer in 2016, Zhongyuan Concord holds a 15% stake in the pan-progeny gene. After the completion of the equity transfer, CICC is the largest shareholder of the generic son gene, holding 12.45%, Wang Sizhen holds 11.90%, the second largest shareholder; Zhongyuan Concord shares fell from 15% in 2016 to 4.24%.
Fresh Fruit refers to the edible fruits of plants with juicy and mainly sweet and sour tastes. Fruit not only contains rich vitamin nutrition, and can promote digestion. AGOLYN offers a variety of fruits such as Fresh apples, Fuji apples, kiwi, pears, lemons and so on .
Fresh Fruit,Fresh Apple,Kiwi Fruit, Fresh Lemon,Fresh Pears
Xi'an Gawen Biotechnology Co., Ltd , https://www.seoagolyn.com